mdxhealth Tissue Test Volume Rebounds 13% Sequentially After Sales Force Restructuring
mdxhealth reported Q2 tissue-based test volume rose 13% sequentially to 12,525 tests, aiding Q2 revenue of $27.2 million, up 16% year over year. Revenue for the first half of 2026 rose 14% to $51.1 million. Liquid Exo mdx volume was 13,578 tests, shifting mix and lowering gross margin to 65.7%. Operating loss widened to $5.1 million. On Aug. 11 it raised $20 million via share placement.
How this was made
The 30-second read
Why it matters
Q2 tissue volume rebounded sequentially, revenue grew, and management reiterated a 2026 revenue target range, but gross margin fell and operating/net losses widened due to ExoDx-related mix and acquisition expenses. A registered direct placement strengthened cash, reducing near-term funding risk.
Market read
Traders get a bundle of actionable datapoints: sequential volume recovery, explicit 2026 revenue guidance range, margin and loss deterioration from mix, and a financing that boosts cash.
What to watch
Investors may underweight the magnitude of operating loss widening and the degree to which tissue growth acceleration is already priced versus the risk that mix continues to dominate profitability.
Background
mdxhealth is integrating ExoDx and restructuring its sales force after commercial disruption tied to the acquisition.
Ticker impact
mdxhealth reported Q2 tissue-based test volume up 13% sequentially and raised/maintained 2026 revenue guidance amid ExoDx integration and sales restructuring.
Near-term bias positive on the guidance and volume rebound, with volatility likely as investors weigh margin dilution from the new revenue mix.
The article provides multiple decision-relevant datapoints: sequential volume rebound, revenue growth, explicit 2026 revenue target range, gross margin decline from mix, and a $20m registered direct placement that changes liquidity.
Market effects
Signals improving commercial execution in prostate diagnostics, but highlights how liquid-based mix can pressure gross margin.
No clear regional-specific impact described.
Limited, focused on company-specific diagnostics performance and integration.
Counterpoint
The sequential tissue rebound may be partly mechanical after customer transition, while the ExoDx-driven mix shift structurally lowers gross margin and keeps losses elevated.
Key entities
- companymdxhealth
Prostate cancer diagnostics company reporting Q2 tissue volume rebound, revenue growth, margin decline, and a $20m registered direct placement.
- product/businessExoDx
Liquid-based diagnostics business being integrated, changing revenue mix and pressuring gross margin.
- product/customer segmentResolve
Customer base transitioned by June 30 as part of commercial restructuring.
- clinical evidenceGPS PROMPT (Oxford study)
Peer-reviewed results cited as supporting market conversion ahead of the PROTECT study.
- clinical programPROTECT study
Landmark study referenced as a future catalyst for market share and conversion.
